Clinical Trial Update: Study of NT-501 Encapsulated Cell Therapy for Glaucoma Neuroprotection and Vision Restoration [Phase 2]

View source ↗

Summary

Phase 2 study of NT-501 Encapsulated Cell Therapy for glaucoma neuroprotection and vision restoration is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glaucoma

Drugs mentioned

• NT-501 Encapsulated Cell Therapy

Snippet

Sponsor: Stanford University | Conditions: Glaucoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING